Exact Therapeutics AS
OSE:EXTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Exact Therapeutics AS
Interest Income Expense
Exact Therapeutics AS
Interest Income Expense Peer Comparison
Exact Therapeutics AS
Glance View
EXACT Therapeutics AS is a clinical stage biopharmaceutical company, which engages in the research and development of novel platform for ultrasound mediated therapeutic amplification. The company is headquartered in Oslo, Oslo and currently employs 8 full-time employees. The company went IPO on 2020-07-14. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The firm's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. The company is done through harnessing the power of ultrasound in combination with ACT formulation.
See Also
What is Exact Therapeutics AS's Interest Income Expense?
Interest Income Expense
533.1k
NOK
Based on the financial report for Dec 31, 2024, Exact Therapeutics AS's Interest Income Expense amounts to 533.1k NOK.
What is Exact Therapeutics AS's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
69%
The average annual Interest Income Expense growth rates for Exact Therapeutics AS have been -9% over the past three years , 69% over the past five years .
